Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Atrial Fibrillation; Stroke Prevention”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)UnknownNCT00247533
What this trial is testing

Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia

Who this might be right for
StrokeCoronary Artery DiseaseArrhythmia
Far Eastern Memorial Hospital 30
Large-scale testing (Phase 3)Study completedNCT00494871
What this trial is testing

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Who this might be right for
Atrial Fibrillation
Bayer 1,280
Not applicableStudy completedNCT02905032
What this trial is testing

SDM for Stroke Prevention in Atrial Fibrillation

Who this might be right for
Atrial Fibrillation
Mayo Clinic 1,186
Not applicableStudy completedNCT01947998
What this trial is testing

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Who this might be right for
Venous ThrombosisPulmonary EmbolismAtrial Fibrillation+1 more
Bayer 50,299
Not applicableStudy completedNCT03568916
What this trial is testing

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Who this might be right for
Atrial FibrillationIschemic StrokeSystemic Embolization+3 more
Canadian Network for Observational Drug Effect Studies, CNODES 227,579
Not applicableActive Not RecruitingNCT06922695
What this trial is testing

Responding to AF: Pill-in-Pocket Anticoagulation Guided by Automated Monitoring and Alerts

Who this might be right for
Atrial Fibrillation (AF)Atrial Fibrillation (Prevention of Stroke)
Oxford University Hospitals NHS Trust 50
Not applicableStudy completedNCT05321810
What this trial is testing

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Who this might be right for
Non-valvular Atrial Fibrillation
Pfizer 193,565
Not applicableStudy completedNCT02344901
What this trial is testing

ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)

Who this might be right for
Thrombotic StrokeAtrial Fibrillation and Flutter
Muğla Sıtkı Koçman University 6,273
Not applicableUnknownNCT06014268
What this trial is testing

Electronic Clinical Decision Support System (eCDSS) for Prevention of Atrial Fibrillation-related Stroke

Who this might be right for
Atrial FibrillationStroke
South London and Maudsley NHS Foundation Trust 20
Post-approval studies (Phase 4)Study completedNCT03126214
What this trial is testing

Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing

Who this might be right for
Atrial FibrillationStroke
University of Alberta 79
Large-scale testing (Phase 3)Study completedNCT00262600
What this trial is testing

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Who this might be right for
Atrial FibrillationStroke
Boehringer Ingelheim 18,113
Not applicableWithdrawnNCT03804125
What this trial is testing

Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery

Who this might be right for
Cerebral StrokeThrombosis, Deep VeinPulmonary Embolism
Pfizer
Not applicableStudy completedNCT01927445
What this trial is testing

Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care

Who this might be right for
Atrial Fibrillation
Sunnybrook Health Sciences Centre 5,000
Not applicableStudy completedNCT03847181
What this trial is testing

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

Who this might be right for
Atrial Fibrillation
Bayer 45,164
Not applicableUnknownNCT05144958
What this trial is testing

Stand-alone Left Atrial Appendage Occlusion for Thromboembolism Prevention

Who this might be right for
Atrial FibrillationStroke
Nicolaus Copernicus University 400
Not applicableStudy completedNCT01925755
What this trial is testing

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Who this might be right for
StrokeEmbolism
Bayer 209
Not applicableStudy completedNCT02262676
What this trial is testing

Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain

Who this might be right for
Atrial Fibrillation
Bayer 2,251
Testing effectiveness (Phase 2)Ended earlyNCT00206063
What this trial is testing

Long Term Open Follow-up With H376/95 vs. Warfarin

Who this might be right for
Stroke Prevention in Patients With Atrial Fibrillation
AstraZeneca 220
Not applicableWithdrawnNCT04684212
What this trial is testing

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

Who this might be right for
Atrial FibrillationLeft Atrial Appendage ThrombosisCVA
Brian O'Neill MD
Not applicableStudy completedNCT02470767
What this trial is testing

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Who this might be right for
StrokePrevention and ControlAtrial Fibrillation
Bayer 792
Next Page